Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Alexandria Real Estate Equities Inc (ARE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Alexandria Real Estate Equities Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Alexandria Real Estate Equities Inc trades at $48.1 (market cap $8.61B). The key difference: Alexandria Real Estate Equities Inc is the larger of the two by market cap, and Alexandria Real Estate Equities Inc pays a 5.83% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ARE | |
|---|---|---|
Market Cap | $4.49B | $8.61B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $87.45 |
52-Week Low | $20.06 | $40.41 |
Enterprise Value | $3.69B | $21.07B |
Dividend Yield | — | 5.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Alexandria Real Estate Equities (ARE) trades at $49.41, down 6.03% over 24 hours amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with -37.09% net income margin and -6.43% ROE, though valuation metrics like P/B of 0.55 suggest potential undervaluation. Recent earnings have been inconsistent with two misses in the last four quarters. The company maintains strong operational cash flow of $1.41B and declared a $0.72 dividend for Q2 2026.
ARE faces headwinds from declining occupancy guidance and net losses, but analyst consensus remains cautiously optimistic with a $51 price target and 37.5% buy ratings. Key risks include high debt levels (40.79% debt-to-asset ratio) and uneven demand in life science real estate. The stock's current position near support at $49 offers potential for recovery if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →
